Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients

Table 3 Autoantibody prevalence in first degree relatives of patients with primary biliary cirrhosis, compared to autoimmune hepatitis-1 and primary sclerosing cholangitis first degree relatives and healthy controls n (%)

Autoantibody	PBC FDRs (n = 101)	AIH-1 and PSC FDRs (n = 40)	Healthy controls (n = 40)	P1	P2
AMA (IIF)	10 (9.9)	1 (2.5)	0	NS	< 0.001
1:80	8 (7.9)	1 (2.5)	-
1:160	1 (1)	-	-
1:320	1 (1)	-	-
IgG MIT3-based ELISA	13 (12.9)	0	0	0.02	0.02
AMA positivity3	19 (18.8)	1 (2.5)	0	0.01	0.003
RL/M pattern	8 (7.9)	1 (2.5)	0	NS	NS
1:80	8 (7.9)	1 (2.5)	-
MND pattern	9 (8.9)	5 (12.5)	0	NS	0.06
1:80	7 (6.9)	3 (7.5)	-
1:160	1 (1.0)	-	-
1:320	-	2 (5.0)	-
1:640	1 (1.0)	-	-
PBC-specific ANA3 positivity	0	1 (2.5)	0	NS	NS

¹Comparison between primary biliary cirrhosis (PBC) first degree relatives (FDRs) and autoimmune hepatitis-1 or primary sclerosing cholangitis (AIH-1/PSC) FDRs; ²comparison between PBC FDRs and healthy controls;

³for definition of antimitochondrial antibodies (AMA) and PBC-specific antinuclear antibodies (ANA) positivity please see text (materials and methods section). IIF: Indirect immunofluorescence; ELISA: Enzyme-linked immunosorbent assay; RL/M: Rim-lime/membranous; MND: Multiple nuclear dot; NS: Not significant.